# Retinal and visual side effects of FGFR, MEK and ALK inhibitors and other targeted drugs: eye examinations and dose rules

Source: https://onco.cc/protocols/retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors/  
OnCo record `retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some targeted cancer drugs can affect the back of the eye or your sight: FGFR inhibitors (erdafitinib, pemigatinib, futibatinib), MEK inhibitors (trametinib, binimetinib, cobimetinib, selumetinib), crizotinib and others. Most of their labels set eye checks and rules for pausing or lowering the dose. Tell your team straight away about any change in your sight.

## Summary

This record sets out what the US label and the EU summary of product characteristics (SmPC) of each drug ask for. No ESMO, ASCO or NCCN guideline on the subject was found, and the review papers cited were all but one funded by a manufacturer.

FGFR inhibitors. Erdafitinib: the US label reports central serous retinopathy or retinal pigment epithelial detachment (CSR/RPED) in 22 per cent of a pooled population, median first onset 46 days, and asks for monthly eye examinations for the first 4 months, then every 3 months, and urgently for visual symptoms, with visual acuity, slit lamp, fundoscopy and optical coherence tomography (OCT). The EU SmPC keeps that schedule and adds an examination before starting and an Amsler grid test at each monthly examination; the US label read names neither. Both withhold for CSR and stop for good if it does not resolve within 4 weeks or is grade 4; the US dose table words the 4-week point as 'consider permanent discontinuation'. Pemigatinib: both texts ask for an examination with OCT before starting, every 2 months for 6 months, then every 3 months. Futibatinib: the US label asks for the same schedule; the EU SmPC asks for an examination before starting, 6 weeks later, and urgently for visual symptoms. The US tables go by symptoms and serial examination; the EU tables for pemigatinib and futibatinib go by visual acuity.

MEK inhibitors. The US labels of trametinib, binimetinib and cobimetinib ask for eye examinations periodically or at regular intervals, with no interval stated, and for any visual disturbance; trametinib and binimetinib ask for an evaluation within 24 hours for loss of vision. Their EU SmPCs set no scheduled examination: patients are assessed for visual symptoms and an eye examination is recommended when they have them (promptly, in the trametinib and binimetinib texts). Selumetinib is the only one of the four whose label asks for an examination before starting (US: comprehensive assessments before and at regular intervals; EU: before starting and for new visual disturbances). Retinal vein occlusion (RVO) means stopping for good in every text that mentions it; the EU cobimetinib SmPC read does not mention it. For RPED or serous retinopathy the hold differs: trametinib up to 3 weeks; binimetinib up to 10 days (US) or up to 2 weeks (EU), for symptomatic disease; cobimetinib up to 4 weeks (US) or until visual symptoms improve to grade 1 or less (EU); selumetinib until resolution (US), or only when visual acuity is reduced (EU).

Others. Crizotinib: the US label recommends a monthly assessment of visual symptoms and stopping for good for a grade 3 or 4 ocular disorder or severe visual loss (best corrected vision less than 20/200; the EU text says 6/60) unless another cause is found; children and young adults with anaplastic large cell lymphoma, and children with inflammatory myofibroblastic tumour, have examinations at baseline, within 1 month and every 3 months. Brigatinib: both dose tables withhold for a grade 2 or 3 visual disturbance, resume at the next lower dose and stop for good at grade 4; the US label also asks for an eye examination at grade 2 or worse, where the EU warning says an evaluation and dose reduction should be considered for severe symptoms. Camizestrant: the US label withholds for grade 2 or worse visual disturbances and refers to an eye care professional; the EU SmPC says to consider referral and leaves interruption to clinical assessment. Datopotamab deruxtecan: the US label asks for an eye examination at the start, visual acuity and slit lamp every 3 cycles and at the end, with lubricant drops at least four times daily; the EU SmPC sets no scheduled examination. Tamoxifen: the US label reports cataracts and other ocular disturbances and asks that women seek prompt medical attention for changes in vision; it sets no examination schedule. The reader's own team's protocol comes first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: FGFR inhibitor retinopathy; MEK inhibitor retinopathy; MEKAR; central serous retinopathy on erdafitinib; retinal pigment epithelial detachment; RPED; serous retinal detachment on pemigatinib; retinal vein occlusion on MEK inhibitors; crizotinib visual disturbance; camizestrant photopsia; Datroway eye care; tamoxifen and cataract; Amsler grid on Balversa

## Connected records

- protocols: [Eye care with antibody-drug conjugates that harm the cornea: belantamab, mirvetuximab, tisotumab and enfortumab](https://onco.cc/protocols/eye-care-with-ocular-toxic-antibody-drug-conjugates/), [Eye side effects of checkpoint inhibitors: dry eye, uveitis and optic neuritis](https://onco.cc/protocols/irae-ocular/), [High phosphate on FGFR inhibitors (erdafitinib, pemigatinib, futibatinib): monitoring, diet, binders and dose rules](https://onco.cc/protocols/hyperphosphataemia-on-fgfr-inhibitors/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Brigatinib](https://onco.cc/drugs/brigatinib/), [Camizestrant](https://onco.cc/drugs/camizestrant/), [Cobimetinib](https://onco.cc/drugs/cobimetinib/), [Crizotinib](https://onco.cc/drugs/crizotinib/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Erdafitinib](https://onco.cc/drugs/erdafitinib/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [Pemigatinib](https://onco.cc/drugs/pemigatinib/), [Selumetinib](https://onco.cc/drugs/selumetinib/), [Trametinib](https://onco.cc/drugs/trametinib/)
- terms: [Ocular toxicity (keratopathy, blurred vision)](https://onco.cc/terms/ocular-toxicity/)

---
JSON: https://onco.cc/api/v1/entities/retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors.json